News

News

Media contacts:
Sandra Wirsching | s.wirsching@biocom.de | +49-30-264 921-63
Clément Robijns | c.robijns@biocom.de | +49-30-264 921-58

US Senate re-introduces PASTEUR Act

The US Senate has reintroduced the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act…

New BARDA Ventures will invest $500m to prepare for future health challenges

BARDA have announced the creation of a new venture to develop and commercialize technologies and medical…

EPSRC funds new programme ‘Beyond Antibiotics’

The 5-year programme will start in October 2021. Scientists from the Universities of Oxford, Ulster and…

Nanotherapeutics Hub joins forces with iiCON

The Nanotherapeutics hub and iiCON step up the UK’s infectious disease R&D pipeline. iiCON, led by…

Second financing for BioVersys from CARB-X

CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in…

GARDP and DNDi publish policy brief at 74th WHA

GARDP together with DNDi published a policy briefing statement at the 74th World Health Assembly. According…

Basilea supported by CARB-X funding

CARB-X is awarding Swiss listed company Basilea Pharmaceutica International up to US $2.7m to develop a novel class…

Sandoz is investing €150m in its antibiotics manufacturing setup in Europe

Sandoz, a Novartis division, has announced plans to invest €150m and further strengthen its European antibiotics…

CARB-X backs Summit Therapeutics with up to $4.1m

Up to $4.1 million in non-dilutive funding are being awarded by CARB-X to UK-based Summit Therapeutics. The capital…

BARDA seeks proposals for new Antibacterial Accelerator

BARDA is seeking proposals for a new Antibacterial Accelerator which is funded for the next ten…

High-level Interactive Dialogue on AMR

End of April the General Assembly High-Level Interactive Dialogue on Tackling AMR took place as a…

Pfizer grows infectious disease pipeline

US pharma company Pfizer acquired US-based biotech company Amplyx Pharmaceuticals for an undisclosed sum. The deal…

Diagnostics company GenomeKey funded by CARB-X

CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive…

X-Biotix stops antibacterial activities

US-based X-Biotix Therapeutics, focused on antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, will suspend its current antibacterial…

Bacteriophage-company Pico Therapeutics backed by CARB-X

CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug…

Update on WHO pipeline report available

The WHO has published their updated analysis for the clinical and preclinical antibacterial product pipeline in…

BioVersys gets €20m EIB loan to develop novel antibiotics

Swiss BioVersys has received €20m from the European Investment Bank to push the development of new…

EU starts consultation process on HERA

The European Commission launched an online public consultation on the Health Emergency Preparedness and Response Authority…

University of Oxford receives funding

CARB-X is awarding up to US$2 million to the Jenner Institute, part of the University of…

Guidance on Stewardship and Access for developers published

Led by Wellcome Trust, a group of AMR funders has published the first guidance on strategies…

New study on national policy options

The Global AMR R&D Hub has published a study on national policy options to reward the…

GSK receives up to $18m CARB-X funding for two vaccine projects

CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH),…

French biotech Mutabilis funded by CARB-X

CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to…

CARB-X will invest up to US$15m for German AMR projects

CARB-X announced the investment of first grants to two German research teams from the German Helmholtz…

CARB-X is funding a team of top German researchers to develop a drug to treat Staphylococcus aureus infections and prevent exacerbation of life-threatening pneumonia

Researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC)…

CARB-X is funding a German team of scientists to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) team could receive up to US$6.31 million if all…

Juvabis Announces Positive Phase 1 Results of EBL-1003 in the Innovative Medicines Initiative’s ENABLE Consortium

Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and…

World leaders join forces to fight the accelerating crisis of antimicrobial resistance

High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors…

First Dynamic Dashboard analysis report and recommendations to the G20

The Global AMR R&D Hub publishes its first report “The state of public and philanthropic investments…

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign. The content…

BioVersys starts Phase 1 Clinical Trial of BV100

BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii…

CARB-X is funding Polyphor to develop a new antibiotic to treat multidrug-resistant Enterobacteriaceae Gram-negative bacterial infections

CARB-X announced today it is awarding up to US$2.62 million to Polyphor AG (SIX:POLN), headquartered in…

The Pharmaceutical Strategy is a chance to tackle antimicrobial resistance that Europe cannot miss says the MEP Interest Group on AMR

On 6 October, the MEP interest group on AMR released an official letter to the EU…

CARB-X funds GSK to develop a new drug for urinary tract infections (UTI) caused by Escherichia coli bacteria

CARB-X announced today it is awarding up to US$7.51 million to GlaxoSmithKline (NYSE: GSK), to develop…

Conference summary: Push for pull incentives

With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs…

Bioversys bags €17.7m financing

Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two…

Start-up pitch winner: FluoretiQ

British diagnostics company FluoretiQ Ltd was selected as start-up pitch winner during the 4th annual AMR…

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics…

What Can Be Learned From COVID-19 to Prevent the Next Health Emergency

Dr Manica Balasegaram, GARDP Executive Director, spoke at the opening of BIOCOM’s 4th AMR Conference on…

Aicuris to launch AiCubator to fight AMR

Antinfectives specialist AiCuris GmbH will launch the “AiCubator”, a new way to collaborate in anti-infectives and…

CARB-X is funding Evotec to develop a new class of broad-spectrum antibiotics

Evotec is the first pharmaceutical R&D company based in Germany in the CARB-X portfolio CARB-X announced…

Cost-efficient and green manufacturing of peptides thanks to Molecular Hiving technology™

Bachem and Jitsubo CO., LTD. recently announced the signature of an exclusive Licensing Agreement for Jitsubo’s…

PBS News Hour story Part II covers recent developments in the AMR field

A remarkable 2-part PBS News Hour story exclusively dedicated to AMR The antibiotics industry has suffered…

COVID-19 and AMR: Part I of the PBS News Hour story reflects the implications of the virus on AMR

A remarkable 2-part PBS News Hour story exclusively dedicated to AMR COVID-19 can be accompanied by…

Spanish vaccine company Vaxdyn receives CARB-X funding

CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent infections that cause…

AMR Action Fund: A $1b down payment from Industry

The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and…

CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics

With a unique approach, Eligo engineers natural predators of bacteria to deliver CRISPR systems that kill…

Pharma giants return to antibiotics huddle to launch $1B venture fund

Big Pharma exited from the antibiotics space one by one – and now they may be…

How data partnerships can help tackle drug-resistant infections

Access to surveillance data crucial to tackling infectious diseases Wellcome Trust has partnered with Pfizer Inc.…

First Australian project in the CARB-X portfolio

CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience,…

CARB-X funds Indian diagnostic company Module Innovations

CARB-X will invest up to $3m into India-based diagnostics company Module Innovations whichis developing a rapid…

The June issue of ACS Infectious Diseases: dedicated to AMR challenges

The June issue of ACS Infectious Diseases is a special issue on antibiotics featuring all major…

GARDP seeks for a biotech industry expert in its board

GARD is looking for a new Board member with high-level executive experience and strategy setting in…

The REPAIR Impact Fund launches new global call

Until 31 July 2020 companies developing new treatments to combat AMR are invited to submit proposals.…

CARB-X invests up to $11m in Microbion

CARB-X is investing up to $11m into US-based Microbion to develop its inhaled drug pravibismane to…

CARB-X funds Facile Therapeutics with up to $18m

CARB-X funds US-based Facile Therapeutics to further develop a new oral drug that would disable toxins…

CARB-X awards Day Zero Diagnostics $6.2M

CARB-X will support US-based Day Zero Diagnostics with $6.2M. The company combines whole-genome sequencing and machine…

WHO calls for new data on preclinical pipeline

Until 25th August companies, institutions and individuals are invited to submit data on their products that…

Manica Balasegaram: “Multi-resistant bacteria are just as threatening”

Faced with antibiotic resistance, pharmaceuticals and governments could be doing much more, warns Manica Balasegaram, Executive Director of GARDP,…

AMR R&D Hub launched Dynamic Dashboard

The Global AMR R&D Hub’s Dynamic Dashboard continuously collects and presents information on AMR R&D investments,…

IMI project COMBINE launched

COMBINE will support the coordination of the Innovative Medicines Initiative (IMI) Antimicrobial Resistance (AMR) Accelerator Programme…

Researchers open up new antibiotic reservoir

For the first time, scientists from Jena succeeded to cultivate and functionally characterize a total of…

BEAM Alliance released memo on PULL incentives

A new EU report sees only slow progress in the fight against AMR. The BEAM Alliance…

AMR: ENABLE selects Mutabilis candidate

A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE…

New players to step into the AMR field

Despite challenging markets new players are entering the field to advance drug development in the fight…

The AMR business (Part I)

Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug…

BioVersys receives up to €8m from CARB-X

Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to…

Polyphor presents AMR breaker

Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action…

IMI AMR Accelerator: Allow the few to make the most of their resources

In 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative…

Procarta Biosystems receives CARB-X funding

UK–based biotech company Procarta Biosystems has been funded by CARB-X to develop a new class of…

India joins the Global AMR R&D hub

India has joined the Global AMR R&D Hub as a new Member. This expands the global…

Antibiotic resistance without use of antibiotics

Swiss researchers from Zurich and Basel have discovered that resistance in intestinal bacteria can spread even…

Public consultation on TPPs for diagnostics

WHO has published target product profiles for diagnostics against antibacterial resistance identified as priorities. Until 29th…

From Melinta Therapeutics to CARB-X

Erin Duffy, former CSO of US biotech company Melinta Therapeutics, replaces Karen Gallant as CARB-X‘s Chief…

CARB-X funds vaccines companies

CARB-X has recently funded several vaccines projects to fight AMR-related infections developed by US-based SutroVax and…

WHO publishes TPPs for needed antibacterial agents

The WHO has developed several draft target products profiles (TPPs) and is seeking feedback from AMR…

Nabriva receives FDA approval for novel antibiotic

Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta…

New IMI project ‘GNA Now’ kicks off battle against antimicrobial resistance

Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel…